COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine.
Francesco FontanaGaetano AlfanoGiacomo MoriAlessio AmurriLorenzo TeiMarco BallestriMarco LeonelliFrancesca FacchiniFrancesca DamianoRiccardo MagistroniGianni CappelliPublished in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020)
Coronavirus disease 2019 (COVID-19) pneumonia has been poorly reported in solid organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61-year-old kidney transplant recipient with several comorbidities who was hospitalized and later received a diagnosis of COVID-19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, transplant clinicians should be readily informed about new cases of COVID-19 pneumonia in solid organ transplant recipients, with focus on therapeutic strategies employed and their outcome.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- mechanical ventilation
- respiratory failure
- rheumatoid arthritis
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- intensive care unit
- acute respiratory distress syndrome
- peritoneal dialysis
- rheumatoid arthritis patients
- prognostic factors
- juvenile idiopathic arthritis
- palliative care
- case report
- disease activity
- extracorporeal membrane oxygenation
- quantum dots